AA
ALBO

AlphaCentric Advisors’s Albireo Pharma Inc ALBO Stock Holding History

AlphaCentric Advisors’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$38K – 226
2020
Q4 		$38K Buy
+1,000
New +$36.4K 0.02% 193

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

AlphaCentric Advisors's ALBO Position: Q1 2021 in Review

AlphaCentric Advisors sold out of Albireo Pharma Inc (ALBO) in Q1 2021, closing a stake of 1,000 shares — an estimated $38K sold.

AlphaCentric Advisors first reported a position in ALBO in Q4 2020 and held it in 1 quarter. The position peaked at $38K in Q4 2020. 100 funds tracked by Wall St. Rank hold ALBO as of Q1 2021.

  • AlphaCentric Advisors reported no remaining Albireo Pharma Inc position as of Q1 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 1,000 Albireo Pharma Inc shares in Q1 2021, an estimated $38K.
  • AlphaCentric Advisors first reported a position in Albireo Pharma Inc in Q4 2020 and held it in 1 quarter.
  • AlphaCentric Advisors's Albireo Pharma Inc position peaked at $38K in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2021.

Based on AlphaCentric Advisors's 13F filing for Q1 2021, filed 9 Mar 2022.